Mayaro Virus: The State-of-the-Art for Antiviral Drug Development

dc.creatorAndreolla, Ana Paula
dc.creatorBorges, Alessandra Abel
dc.creatorBordignon, Juliano
dc.creatorSantos, Claudia Nunes Duarte dos
dc.date2023-05-04T13:50:08Z
dc.date2023-05-04T13:50:08Z
dc.date2022
dc.date.accessioned2023-09-26T20:50:53Z
dc.date.available2023-09-26T20:50:53Z
dc.identifierANDREOLLA, Ana Paula et al. Mayaro Virus: the State-of-the-Art for antiviral drug development. Viruses, v. 14, p. 1-21, Aug. 2022.
dc.identifier1999-4915
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/58126
dc.identifier10.3390/v14081787
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8864948
dc.descriptionMayaro virus is an emerging arbovirus that causes nonspecific febrile illness or arthralgia syndromes similar to the Chikungunya virus, a virus closely related from the Togaviridae family. MAYV outbreaks occur more frequently in the northern and central-western states of Brazil; however, in recent years, virus circulation has been spreading to other regions. Due to the undifferentiated initial clinical symptoms between MAYV and other endemic pathogenic arboviruses with geographic overlapping, identification of patients infected by MAYV might be underreported. Additionally, the lack of specific prophylactic approaches or antiviral drugs limits the pharmacological management of patients to treat symptoms like pain and inflammation, as is the case with most pathogenic alphaviruses. In this context, this review aims to present the state-of-the-art regarding the screening and development of compounds/molecules which may present anti-MAYV activity and infection inhibition.
dc.formatapplication/pdf
dc.languageeng
dc.publisherMDPI
dc.rightsopen access
dc.subjectArbovirus
dc.subjectArthritogenic alphavirus
dc.subjectMayaro virus
dc.subjectAntivirals
dc.titleMayaro Virus: The State-of-the-Art for Antiviral Drug Development
dc.typeArticle


Este ítem pertenece a la siguiente institución